Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Tumour mutation status and sites of metastasis in patients with cutaneous melanoma

Adler NR, Wolfe R, Kelly JW, Haydon A, McArthur GA, McLean CA, Mar VJ

(2017), Br J Cancer, 117(7), 1026-35

DOI: 10.1038/bjc.2017.254

Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalá M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM

(2017), N Engl J Med, 377(19), 1813-23

DOI: 10.1056/NEJMoa1708539

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, Haydon A

(2017), Br J Cancer, 117(7), 921-4

DOI: 10.1038/bjc.2017.253

Metastatic pathways in patients with cutaneous melanoma

Adler NR, Haydon A, McLean CA, Kelly JW, Mar VJ

(2017), Pigment Cell Melanoma Res, 30(1), 13-27

DOI: 10.1111/pcmr.12544

Immunotherapy for bladder cancer: rediscovering an old friend

Voskoboynik M, Rudman S, Arkenau HT, Hughes S, Chowdhury S

(2016), BJU Int, 117(5),

The Victorian Melanoma Service: a 20-year review of an Australian multidisciplinary cancer service

Meani RE, Pan Y, McLean C, Haydon A, Leung M, Kelly JW

(2016), Australas J Dermatol, 57(3),

Complete pathological response after neoadjuvant long-course chemoradiotherapy for rectal cancer and its relationship to the degree of T3 mesorectal invasion

Wilkins S, Haydon A, Porter I, Oliva K, Staples M, Carne P, McMurrick P, Bell S

(2016), Dis Colon Rectum, 59(5),

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro

(2016), J Clin Oncol, 34(19),

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapi

(2016), BMC Cancer, 16,

A randomized controlled trial of a nurse-led supportive care package (SurvivorCare) for survivors of colorectal cancer

Jefford M, Gough K, Drosdowsky A, Russell L, Aranda S, Butow P, Phipps-Nelson J, Young J, Krishnasamy M, Ugalde A, King D, Strickland A, Franco M, Blum R, Johnson C, Ganju V, Shapiro J, Chong G, Charlton J, Haydon A, Schofield P

(2016), Oncologist, 21(8),

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelste

(2016), Sci Transl Med, 8(346),

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists

Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J

(2016), Asia Pac J Clin Oncol, 12 Suppl 7,

Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma

Voskoboynik M, Mar V, Mailer S, Colebatch A, Fennessy A, Logan A, Hewitt C, Cebon J, Kelly J, McArthur G

(2016), Pigment Cell Melanoma Res, 29(2),

Challenges of patient selection for Phase I oncology trials

Voskoboynik M, Arkenau H-T

(2015), In: Vallisuta O, Olimat S (eds), Drug Discovery and Development - From Molecules to Medicine, InTech, Croatia, Chapter 3, 65-82

Advanced melanoma: the changing landscape of treatment

Haydon A, Moore M

(2015), Med Today, 16(9), 58-61

Long survival (cure) to cisplatin/infusional 5-flurouracil in metastatic squamous cell anal cancer with extensive liver and lung metastases

Haydon A, Tay R, Mak G, Shapiro J

(2015), Case Rep Clin Med, 4(3), 73-6

Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma

Klein O, Davis ID, McArthur GA, Chen L, Haydon A, Parente P, Dimopoulos N, Jackson H, Xiao K, Maraskovsky E, Hopkins W, Stan R, Chen W, Cebon J

(2015), Cancer Immunol Immunother, 64(4), 507-18

A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A

(2015), Ann Oncol, 26(11), 2267-74

Prognosis associated with cutaneous melanoma metastases

Pan Y, Haydon AM, McLean CA, McDonald PB, Kelly JW

(2015), Australas J Dermatol, 56(1), 25-8

Principles of Medical Therapy

George M, Schwarz M, McKinnon R

(2014), In: Sabesan S, Olver I (eds), Clinical Oncology for Medical Students. Sydney: Cancer Council Australia, Chapter 10,

6 7 8 9 10